Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL859949 | 0.82 | NPC1 (0.32) | NPC1RAB9A | |
| SCHEMBL3269312 | 0.77 | NPC1 (0.39) | NPC1RAB9A | |
| SCHEMBL16995085 | 0.74 | ALDH1A1 (0.37) | NPC1RAB9A | |
| SCHEMBL19945626 | 0.73 | — | — | |
| SCHEMBL19945625 | 0.72 | — | — | |
| SCHEMBL12035804 | 0.72 | ALDH1A1 (0.33) | — | |
| SCHEMBL1503828 | 0.71 | HPGD (0.37) | — | |
| SCHEMBL25409486 | 0.68 | TSHR (0.44) | NPC1RAB9A | |
| SCHEMBL21132564 | 0.65 | NPC1 (0.35) | NPC1RAB9A | |
| SCHEMBL19185762 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10787430-B2 | Hemoglobin modifier compounds and uses thereof | FRONTHERA U.S. PHARMACEUTICALS LLC (US) | 2020-09-29 | — | — | US | disclosed |
| US-20190330181-A1 | HEMOGLOBIN MODIFIER COMPOUNDS AND USES THEREOF | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2019-10-31 | — | — | US | disclosed |
| WO-2017218960-A1 | HEMOGLOBIN MODIFIER COMPOUNDS AND USES THEREOF | FRONTHERA U.S. PHARMACEUTICALS LLC (US) | 2017-12-21 | — | — | WO | disclosed |
| WO-2010142934-A1 | INDOLE DERIVATIVES AS LIGANDS OF CRTH2 RECEPTORS | PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) | 2010-12-16 | — | — | WO | disclosed |
| EP-1735302-B1 | 4-AMINO-PIPERIDINE DERIVATIVES AS MONOAMINE UPTAKE INHIBITORS | LILLY CO ELI (US) | 2010-06-16 | — | — | EP | disclosed |
| US-7521462-B2 | 4-Amino-piperidine derivatives as monoamine uptake inhibitors | ELI LILLY AND COMPANY (US) | 2009-04-21 | — | — | US | disclosed |
| US-20070093526-A1 | 4-Amino-piperidine derivatives as monoamine uptake inhibitors | ELI LILLY AND COMPANY (US) | 2007-04-26 | — | — | US | disclosed |
| EP-1735302-A1 | 4-AMINO-PIPERIDINE DERIVATIVES AS MONOAMINE UPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005092885-A1 | 4-AMINO-PIPERIDINE DERIVATIVES AS MONOAMINE UPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093526-A1 | 4-Amino-piperidine derivatives as monoamine uptake inhibitors | SLC18A2, SLC6A2, SLC6A3 | NPC1 441/4885RAB9A 1140/4885 |
| US-20190330181-A1 | HEMOGLOBIN MODIFIER COMPOUNDS AND USES THEREOF | HBB, HBG1, HBG2 | NPC1 2587/4885RAB9A 3233/4885 |
| US-10787430-B2 | Hemoglobin modifier compounds and uses thereof | HBB, HBG1, HBG2 | NPC1 2587/4885RAB9A 3233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.